Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $109.1 million.

  • CorMedix's Accumulated Expenses rose 54271.22% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.1 million, marking a year-over-year increase of 54271.22%. This contributed to the annual value of $32.0 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, CorMedix's Accumulated Expenses stood at $109.1 million, which was up 54271.22% from $25.7 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Accumulated Expenses ranged from a high of $109.1 million in Q3 2025 and a low of $1.4 million during Q1 2021
  • Over the past 5 years, CorMedix's median Accumulated Expenses value was $4.2 million (recorded in 2021), while the average stood at $14.7 million.
  • Per our database at Business Quant, CorMedix's Accumulated Expenses tumbled by 6786.53% in 2021 and then skyrocketed by 54271.22% in 2025.
  • CorMedix's Accumulated Expenses (Quarter) stood at $3.0 million in 2021, then skyrocketed by 31.84% to $4.0 million in 2022, then rose by 29.3% to $5.1 million in 2023, then skyrocketed by 521.84% to $32.0 million in 2024, then surged by 241.43% to $109.1 million in 2025.
  • Its Accumulated Expenses was $109.1 million in Q3 2025, compared to $25.7 million in Q2 2025 and $32.3 million in Q1 2025.